Trait: hypertrophic cardiomyopathy

Experimental Factor Ontology (EFO) Information
Identifier EFO_0000538
Description A condition in which the myocardium is hypertrophied without an obvious cause. The hypertrophy is generally asymmetric and may be associated with obstruction of the ventricular outflow tract. [NCIT: C34449]
Trait category
Cardiovascular disease
Synonyms 38 synonyms
  • Asymmetric Septal Hypertrophies
  • Asymmetric Septal Hypertrophy
  • Cardiomyopathies, Hypertrophic
  • Cardiomyopathies, Hypertrophic Obstructive
  • Cardiomyopathy, Hypertrophic Obstructive
  • Cardiomyopathy, hypertrophic
  • HCM
  • HCM - Hypertrophic cardiomyopathy
  • HOCM - Hypertrophic obstructive cardiomyopathy
  • HYPERTR OBSTR CARDIOMYOP
  • Hypertrophic Cardiomyopathies
  • Hypertrophic Obstructive Cardiomyopathies
  • Hypertrophic Obstructive Cardiomyopathy
  • Hypertrophic cardiomyopathy (disorder)
  • Hypertrophic obstructive cardiomyopathy (disorder)
  • Hypertrophies, Asymmetric Septal
  • Hypertrophy, Asymmetric Septal
  • IDIOPATHIC HYPERTROPHIC SUBVALV STENOSIS
  • IHSS
  • IHSSs
  • Idiopathic Hypertrophic Subaortic Stenosis
  • Idiopathic Hypertrophic Subvalvular Stenosis
  • Obstructive Cardiomyopathies, Hypertrophic
  • Obstructive Cardiomyopathy, Hypertrophic
  • Obstructive cardiomyopathy
  • Primary hypertrophic cardiomyopathy
  • SUBVALV STENOSIS
  • SUBVALV STENOSIS IDIOPATHIC HYPERTROPHIC
  • Septal Hypertrophies, Asymmetric
  • Septal Hypertrophy, Asymmetric
  • Subvalvular Stenosis, Idiopathic Hypertrophic
  • hyper. obst. cardiomyopathy
  • hypertrophic cardiomyopathy
  • hypertrophic myocardiopathy
  • hypertrophic obstructive cardiomyopathy
  • hypertrophic subaortic stenosis
  • obstructive hypertrophic cardiomyopathy
  • primary hypertrophic cardiomyopathy (disorder) [Ambiguous]
Mapped terms 36 mapped terms
  • DOID:11984
  • ICD10:I42.1
  • ICD9:425.1
  • ICD9:425.11
  • ICD9:425.4
  • KEGG:05410
  • MESH:D002312
  • MONDO:0005045
  • MeSH:D002312
  • MedDRA:10020871
  • NCIT:C34449
  • NCIT:C84773
  • NCIt:C34449
  • OMIM:115196
  • OMIM:115197
  • OMIM:192600
  • OMIM:600858
  • OMIM:601493
  • OMIM:608751
  • OMIM:612098
  • OMIM:613251
  • OMIM:613255
  • OMIM:613690
  • OMIM:613765
  • OMIM:613838
  • OMIM:613873
  • OMIM:613874
  • OMIM:613875
  • OMIM:613876
  • OMIM:618052
  • OMIMPS:192600
  • ORDO:Orphanet_217569
  • Orphanet:217569
  • SCTID:233873004
  • SNOMEDCT:233873004
  • UMLS:C0007194

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported
Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution Scoring File (FTP Link)
PGS000739
(HCM_GRS)
PGP000146 |
Harper AR et al. Nat Genet (2021)
Hypertrophic cardiomyopathy hypertrophic cardiomyopathy 27
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000739/ScoringFiles/PGS000739.txt.gz
PGS000778
(PRSHCM)
PGP000182 |
Tadros R et al. Nat Genet (2021)
Hypertrophic cardiomyopathy hypertrophic cardiomyopathy 20
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000778/ScoringFiles/PGS000778.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001765 PGS000739
(HCM_GRS)
PSS000909|
Multi-ancestry (including European)|
41,597 individuals
PGP000146 |
Harper AR et al. Nat Genet (2021)
Reported Trait: Hypertrophic cardiomyopathy OR: 1.73 [1.63, 1.83] Age, gender, PCs(1-10)
PPM001767 PGS000739
(HCM_GRS)
PSS000910|
Multi-ancestry (including European)|
20,501 individuals
PGP000146 |
Harper AR et al. Nat Genet (2021)
Reported Trait: Hypertrophic cardiomyopathy carrying a pathogenic sarcomere mutation OR: 1.54 [1.39, 1.69] Age, gender, PCs(1-10)
PPM001766 PGS000739
(HCM_GRS)
PSS000908|
Multi-ancestry (including European)|
21,095 individuals
PGP000146 |
Harper AR et al. Nat Genet (2021)
Reported Trait: Hypertrophic cardiomyopathy in individuals who do not carry a pathogenic sarcomere mutation OR: 1.8 [1.67, 1.93] Age, gender, PCs(1-10)
PPM002016 PGS000778
(PRSHCM)
PSS000999|
Ancestry Not Reported|
368 individuals
PGP000182 |
Tadros R et al. Nat Genet (2021)
Reported Trait: Clinical events in individuals with a pathogenic or likely pathogenic sarcomeric variant HR: 1.28 [1.06, 1.54]
β: 0.247 (0.095)
Genetic relatedness matrix, sex Clinical events includes time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death, appropriate ICD therapy or atrial fibrillation/flutter.
PPM002017 PGS000778
(PRSHCM)
PSS001000|
Ancestry Not Reported|
368 individuals
PGP000182 |
Tadros R et al. Nat Genet (2021)
Reported Trait: Major clinical events in individuals with a pathogenic or likely pathogenic sarcomeric variant HR: 1.29 [1.04, 1.59]
β: 0.255 (0.108)
Genetic relatedness matrix, sex Major clinical events includes time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death or appropriate ICD therapy.
PPM002018 PGS000778
(PRSHCM)
PSS001004|
Ancestry Not Reported|
368 individuals
PGP000182 |
Tadros R et al. Nat Genet (2021)
Reported Trait: Septal reduction therapy in individuals with a pathogenic or likely pathogenic sarcomeric variant HR: 1.36 [1.06, 1.74]
β: 0.304 (0.127)
Genetic relatedness matrix, sex Septal reduction therapy includes time time to septal myectomy or alcohol septal ablation.
PPM002020 PGS000778
(PRSHCM)
PSS001003|
Ancestry Not Reported|
194 individuals
PGP000182 |
Tadros R et al. Nat Genet (2021)
Reported Trait: Maximal left ventricular wall thickness indexed to body surface area (mm/m^2) in individuals with a pathogenic or likely pathogenic sarcomeric variant β: 0.731 (0.238) Genetic relatedness matrix Each standard deviation increase in the polgyenic risk score is associated with 0.7 mm m^-2 increase in maximal left ventricular wall thickness.
PPM002021 PGS000778
(PRSHCM)
PSS001002|
Ancestry Not Reported|
214 individuals
PGP000182 |
Tadros R et al. Nat Genet (2021)
Reported Trait: Clinical events in in individuals with a pathogenic or likely pathogenic sarcomeric variant HR: 1.53 [1.05, 2.22]
β: 0.422 (0.193)
Genetic relatedness matrix, sex Clinical events includes time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death, appropriate ICD therapy or atrial fibrillation/flutter.
PPM002015 PGS000778
(PRSHCM)
PSS001001|
Ancestry Not Reported|
322 individuals
PGP000182 |
Tadros R et al. Nat Genet (2021)
Reported Trait: Maximal left ventricular wall thickness indexed to body surface area (mm/m^2) in individuals with a pathogenic or likely pathogenic sarcomeric variant β: 0.726 (0.188) Genetic relatedness matrix Each standard deviation increase in the polgyenic risk score is associated with 0.7 mm m^-2 increase in maximal left ventricular wall thickness.

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000908 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 17 cases
  • , 545 controls
]
African unspecified GEL, RBH-CRB
PSS000908 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 1 cases
  • , 39 controls
]
Other admixed ancestry Ad Mixed American GEL, RBH-CRB
PSS000908 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 0 cases
  • , 126 controls
]
East Asian GEL, RBH-CRB
PSS000908 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 1,083 cases
  • , 16,072 controls
]
European GEL, RBH-CRB
PSS000908 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 53 cases
  • , 1,510 controls
]
South Asian GEL, RBH-CRB
PSS000908 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 26 cases
  • , 1,623 controls
]
Not reported GEL, RBH-CRB
PSS000909 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 17 cases
  • , 1,098 controls
]
African unspecified GEL, RBH-CRB
PSS000909 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 1 cases
  • , 88 controls
]
Other admixed ancestry Ad Mixed American GEL, RBH-CRB
PSS000909 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 2 cases
  • , 265 controls
]
East Asian GEL, RBH-CRB
PSS000909 Cases were individuals with hypertrophic cardiomyopathy. In the individuals recruited from the Netherlands, this was identified using current diagnostic criteria(eft ventricular wall thickness ≥15mm or ≥13mm in presence of family history)
[
  • 1,653 cases
  • , 32,170 controls
]
European GEL, RBH-CRB
PSS000909 Cases were individuals with hypertrophic Cardiomyopathy.
[
  • 62 cases
  • , 2,974 controls
]
South Asian GEL, RBH-CRB
PSS000909 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 34 cases
  • , 3,233 controls
]
Not reported GEL, RBH-CRB
PSS000910 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 0 cases
  • , 559 controls
]
African unspecified GEL, RBH-CRB
PSS000910 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 0 cases
  • , 38 controls
]
Other admixed ancestry Ad Mixed American GEL, RBH-CRB
PSS000910 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 2 cases
  • , 132 controls
]
East Asian GEL, RBH-CRB
PSS000910 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 569 cases
  • , 16,120 controls
]
European GEL, RBH-CRB
PSS000910 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 9 cases
  • , 1,441 controls
]
South Asian GEL, RBH-CRB
PSS000910 Cases were individuals with hypertrophic cardiomyopathy.
[
  • 8 cases
  • , 1,623 controls
]
Not reported GEL, RBH-CRB
PSS000999 All individuals were carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). Cases included individuals who had experienced a clinical event, defined as: time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death, appropriate ICD therapy or atrial fibrillation/flutter.
[
  • 122 cases
  • , 246 controls
]
Not reported ERSPC
PSS001000 All individuals were carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). Cases included individuals who had experienced a major ventricular arrhythmia, defined as: time to sustained ventricular arrhythmia, appropriate ICD therapy or sudden cardiac death.
[
  • 30 cases
  • , 338 controls
]
Not reported ERSPC
PSS001001 All individuals were carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). The primary outcome of maximal left ventricular wall thickness is defined as maxLVWT indexed to body surface area (BSA) on last available CMR or TTE prior to septal reduction therapy and cardiac transplantation. LVWT from CMR used whenever available unless TTE performed more than 5 years after last CMR. 322 individuals Not reported ERSPC
PSS001002 All individuals were non-proband carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). Cases included individuals who had experienced a clinical event, defined as: time to septal reduction therapy, cardiac transplantation, sustained ventricular arrhythmia, sudden cardiac death, appropriate ICD therapy or atrial fibrillation/flutter.
[
  • 33 cases
  • , 181 controls
]
Not reported ERSPC
PSS001003 All individuals were non-proband carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). The primary outcome of maximal left ventricular wall thickness (maxLVWT) is defined as maxLVWT indexed to body surface area (BSA) on last available CMR or TTE prior to septal reduction therapy and cardiac transplantation. LVWT from CMR used whenever available unless TTE performed more than 5 years after last CMR. 194 individuals Not reported ERSPC
PSS001004 All individuals were carriers of a pathogenic or likely pathogenic variant (MYBPC3 truncating variant, MYBPC3 non-truncating variant, MYH7 variant, MYL2 variant, other genetic variant). Cases included individuals who had experienced septal reduction therapy, defined as: time to septal myectomy or alcohol septal ablation.
[
  • 66 cases
  • , 302 controls
]
Not reported ERSPC